Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.
Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.
Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.
Resignations stymied the Office of Pharmaceutical Quality's beginning.
AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.
AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.
The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.
A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.
Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.
AbbVie's board to reconsider Shire move; docs warm up to ACA; Eisai orphan thyroid cancer drug receives Priority Review.
Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.
The FDA will vote for or against the breast cancer drug by April 13, 2015.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Ireland plans on closing off a tax advantage but pharma does not appear to flinch.
BMS, Janssen and Pharmacyclics to test Opdivo/Imbruvica pairing; Google's latest health experiment will connect docs and patients over video-conferencing Hangouts tool; Five Ranbaxy execs resign after generics firm was acquired by Sun.
The sofosbuvir-ledipasvir combo is expected to run the average genotype 1 patient $80,000.
Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.
The company is working with the FDA on new clinical trial requirements.
Endo to acquire Auxilium for an estimated $2.6bn; Novartis says good-bye to three execs; NIH opens wallet for rare disease research; CMS's Open Payments show financial disparity between men and women; Clarient and GSK collaborate in cancer testing.
The company says ABP 510 hit its primary endpoint in an adalimumab comparison.
In short: more antibotic prescriptions are written in the afternoon than in the morning.
The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.
Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.
The drugmaker is poised to cut 14 pipeline projects loose.
Cigna said found paying for medications and hospitalizations were top healthcare concerns.
Genentech's decision to pare access to three breast cancer drugs has spurred hospitals to take action.
Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.
An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.
Novartis BMS collaboration to evaluate Opdivo paired with three lung cancer treatments; Forbes weighs in on 60 Minutes segment; Sanofi management disagreements delay established drug portfolio sale; FDA sets price for Rare Pediatric Disease Priority Review vouchers; the GPhA challenges lawmakers' misconceptions of generic drug prices.
Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep
Eli Lilly said it discontinued tabalumab, a drug being tested in Phase-III trials for lupus, after it failed to outperform the standard of care.
Government, charities spur production of Ebola treatment Zmapp; Venture capital likes digital health this year; Eli Lilly abandons lupus drug after disappointing Phase-III trial.
A survey shows sales rep bans are accelerating, while also pointing to a limited-time opportunity for pharma to become a significant partner for healthcare systems.
Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.
The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.
A survey shows fewer payers expect more restrictive policies in the near-term.
The reveal comes days before hydrocodone products jump to a more restrictive access tier.
New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.
Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.
The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.
Mobile health devices may be more than they appear to be—consumers are taking an open-source approach to getting the monitors they want.
Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.
US government looks for alternative, nondrug, pain relief options for veterans; Gilead's HCV combo scores positive opinion in EU; FDA reopens commentary for social media draft guidance.
MyStar Connect—available in Europe—translates glucose readings into actionable graphics.
The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.
Final guidance will float in around January, but the news puts Janssen and AbbVie on notice.
The reason: opioids.
Pfizer tries to acquire Actavis; PhRMA says FDA social media rules are bad for consumers; US diabetes rates begin to slow.
The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action.
The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
The bill proposes fining branded drugmakers for not complying.
The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.
GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.
Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
The drugstore chain has lowered its forecast, and generics are just one reason.
Plans to unwind the Suffern, NY, site move forward this winter.
Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.
Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.
The Department of Justice is looking into Medicaid pricing.
Switzerland is pushing Roche to lower its prices on Perjeta
HealthKit off to a bumpy start; Endo offers $2.2 billion for Auxilium; Gilead advanced pancreatic cancer drug fails in trial.
Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.
Analysts do not expect odanacatib to be a major earner.
The designation is for diabetic retinopathy for patients with diabetic macular edema.
Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.
Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.
Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.
With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.
The plan is to bring in-house products to the market as well as through acquisitions.
The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."
Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.
Bloomberg reports that India's Wockhardt has become an M&A target.
Pfizer will sell two Novartis drugs in the UK.
Sales reps are among the pinked-slipped in Spain.
The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.
The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."
Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.
Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.
Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.
The FDA has approved Arnuity Ellipta for asthma.
Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.
AstraZeneca announced the end of the investigation Tuesday.
Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.
GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.
Layoffs are reported to be in the offing.
Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.
Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.
The company is calling the move a withdrawal, as opposed to a recall.
The meningitis and encephalitis medications earned a combined $300 million last year.
The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.
AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.
The majority of the layoffs will be in the US.
Patent losses and lost co-promotion agreements put a dent in sales.
The company refutes a Financial Times rumor that one was happening soonish.
A study indicates they may do little to reduce the risk of stroke or heart attack.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.